Bristol-Myers Squibb has completed a major expansion at its Devens, Massachusetts biologics facility. The $280 million project adds two new buildings to the 89-acre Devens campus: a Biologics Development Building for designing processes for the early production of investigational medicines, and a Clinical Manufacturing Building where investigational medicines will be produced to support clinical trials. Both are new capabilities for Devens, a site that had previously focused solely on large-scale, bulk biologics manufacturing.

The expansion increases the site's workforce, with approximately 200 new jobs having been added at the project's initial completion rising to approximately 350 jobs over time. The two new buildings also add approximately 200,000 square feet to a site now comprised of eight major buildings in a 600,000 square-foot complex. Furthermore, the buildings add to the major investment the company has made at Devens, a former military base. When combined with the company's initial $750 million investment to build the facility, the expansion project brings the company's total investment at the site to more than $1 billion.

The buildings also continue the company's commitment to sustainability in its buildings and operations. The Biologics Development Building has received Leadership in Energy and Environmental Design (LEED) Silver certification for energy and environmental design, and the Clinical Manufacturing Building is also targeted for LEED Silver certification. Sustainable features in the new buildings include an abundance of natural light, a green roof, high efficiency lighting and water systems, water-efficient landscaping, and wood products from sustainable sources. The site's original lab and office building had previously received LEED Gold certification while the manufacturing building received Silver.

Source: Bristol-Myers Squibb